Key result
Telmisartan significantly reduced the recurrence of atrial fibrillation episodes compared to carvedilol (14.3% vs. 37.1%; p<0.003) in hypertensive patients.
Why the study?
Does telmisartan reduce atrial fibrillation recurrence compared to carvedilol in mild hypertensive outpatients with a history of AF?
Population
132 mild hypertensive outpatients in sinus rhythm who had experienced ≥ 1 electrocardiogram-documented AF…
Comparison
Telmisartan 80 mg/day vs Carvedilol 25 mg/day
Design
RCT, Randomly assigned
Follow-up
one year
Authors
Loading...
Telmisartan may be preferred over carvedilol for secondary AF prevention in hypertension; extends randomized evidence for ARBs beyond BP control.
RCT (n=132)
Yes
Does telmisartan reduce atrial fibrillation recurrence compared to carvedilol in mild hypertensive outpatients with a history of AF?
Absolute Event Rate: 14.3% vs 37.1%
p-value: p=<0.003
Telmisartan is significantly more effective than carvedilol in preventing recurrent atrial fibrillation in hypertensive patients, independent of its blood pressure-lowering effects.
Galzerano et al. (2012) conducted an RCT in Hypertension and Atrial Fibrillation (n=132). Telmisartan vs. Carvedilol 25 mg/day was evaluated on Recurrent atrial fibrillation episodes (p=<0.003). Telmisartan significantly reduced the recurrence of atrial fibrillation episodes compared to carvedilol (14.3% vs. 37.1%; p<0.003) in hypertensive patients.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: